Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540023 | 0.89 | DGAT1 (0.80) | DGAT1NPC1RAB9AKMT2ASOAT1 | |
| SCHEMBL3540235 | 0.86 | DGAT1 (0.75) | DGAT1NPC1RAB9AKMT2ASOAT1 | |
| SCHEMBL3544716 | 0.86 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL3543663 | 0.86 | DGAT1 (0.80) | DGAT1NPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL3548050 | 0.86 | DGAT1 (0.64) | DGAT1SOAT1 | |
| SCHEMBL3547403 | 0.84 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3543051 | 0.84 | DGAT1 (0.80) | DGAT1NPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL3546313 | 0.83 | DGAT1 (0.75) | DGAT1NPC1RAB9A | |
| SCHEMBL3548231 | 0.83 | DGAT1 (0.75) | DGAT1NPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL3543610 | 0.82 | DGAT1 (0.86) | DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885NPC1 423/4885RAB9A 2923/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885NPC1 399/4885RAB9A 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.